Department of Medicine, Faculty of Medicine and Health Sciences (FMHS), Universiti Malaysia Sarawak (UNIMAS), Jalan Datuk Mohammad Musa, 94300, Kota Samarahan, Sarawak, Malaysia.
Laboratory of Transcriptional Regulation in Leukemogenesis, International Research Center for Medical Sciences (IRCMS), Kumamoto University, 2-2-1 Honjo, Kumamoto, 860-0811, Japan.
Int J Hematol. 2020 Feb;111(2):217-224. doi: 10.1007/s12185-019-02768-x. Epub 2019 Nov 9.
The BCR-ABL1 fusion gene is the driver mutation of Philadelphia chromosome-positive chronic myeloid leukemia (CML). Its expression level in CML patients is monitored by a real-time quantitative polymerase chain reaction defined by the International Scale (qPCR). BCR-ABL1 has also been found in asymptomatic normal individuals using a non-qPCR method. In the present study, we examined the prevalence of BCR-ABL1 in a normal population in southern Sarawak by performing qPCR for BCR-ABL1 with ABL1 as an internal control on total white blood cells, using an unbiased sampling method. While 146 of 190 (76.8%) or 102 of 190 (53.7%) samples showed sufficient amplification of the ABL1 gene at > 20,000 or > 100,000 copy numbers, respectively, in qPCR, one of the 190 samples showed amplification of BCR-ABL1 with positive qPCR of 0.0023% and 0.0032% in two independent experiments, the sequence of which was the BCR-ABL1 e13a2 transcript. Thus, we herein demonstrated that the BCR-ABL1 fusion gene is expected to be present in approximately 0.5-1% of normal individuals in southern Sarawak.
BCR-ABL1 融合基因是费城染色体阳性慢性髓性白血病(CML)的驱动突变。其在 CML 患者中的表达水平通过国际标准(qPCR)定义的实时定量聚合酶链反应进行监测。使用非 qPCR 方法也在无症状的正常个体中发现了 BCR-ABL1。在本研究中,我们通过使用 qPCR 对总白细胞中的 BCR-ABL1 进行检测,并以 ABL1 作为内部对照,采用无偏采样方法,在砂拉越南部的正常人群中检查了 BCR-ABL1 的流行率。在 qPCR 中,分别有 146 个或 102 个样本的 ABL1 基因扩增超过 20,000 或超过 100,000 个拷贝数,占 190 个样本的 76.8%或 53.7%,但有一个样本的 BCR-ABL1 基因扩增呈阳性,在两个独立的实验中 qPCR 的阳性率分别为 0.0023%和 0.0032%,其序列为 BCR-ABL1 e13a2 转录本。因此,我们在此证明 BCR-ABL1 融合基因预计存在于砂拉越南部约 0.5-1%的正常个体中。